The R&D day will feature presentations by key opinion leaders,
Agenda and Approximate Times for Discussion Topics
1:00-1:05 Welcome and Introductions -
1:05-1:35 TRiMTM Platform and Pipeline Review -
1:35-1:55 Hepatitis B -
1:55-2:05 ARO-HBV -
2:05-2:25 Alpha-1 Antitrypsin Deficiency Liver Disease -
2:25-2:35 ARO-AAT -
2:35-2:55 Hypertriglyceridemia -
2:55-3:05 ARO-APOC3 and ARO-ANG3 -
3:05-3:15 Concluding Remarks -
3:15-3:35 Q & A - Panel
Select R&D Day Highlights
Targeted RNAi Molecule Platform (TRiMTM)
Arrowhead's Targeted RNAi Molecule platform, or TRiMTM, utilizes ligand-mediated delivery and is designed to enable multi-tissue targeting, while being structurally simple. Active targeting has been core to Arrowhead's development strategy and the TRiMTM platform builds on more than a decade of work on actively targeted drug delivery vehicles. Arrowhead scientists now have the ability to progressively "TRiM" away extraneous features and chemistries and retain optimal pharmacologic activity.
New drug candidates utilizing this technology can achieve high levels of target gene knockdown, without an active endosomal escape component, as was required with prior technology platforms.
The TRiMTM platform represents an evolution in RNAi therapeutics from biologic complexity to small molecule precision and execution. The TRiMTM platform comprises the following components optimized, as needed, for each drug candidate: high affinity targeting ligands; various linker chemistries; structures that enhance pharmacokinetics; and highly potent RNAi triggers with sequence specific stabilization chemistries. The platform offers several competitive advantages, including:
Arrowhead believes that for RNAi to reach its true potential, it must target organs outside the liver. Arrowhead is leading this expansion with the TRiMTM platform that holds the promise of reaching multiple tissues, including the lung and tumors. ARO-Lung1, the first candidate against an undisclosed gene target in the lung, reached almost 90% target knockdown following inhaled administration in rodents. In addition, the ARO-HIF2 candidate targeting renal cell carcinoma achieved 85% target gene knockdown in a rodent tumor model. Clinical Trial Authorization (CTA) filings are planned in Q4 2018 and in 2019 for ARO-Lung1 and ARO-HIF2, respectively.
ARO-AAT, Arrowhead's second generation subcutaneously administered clinical candidate for the treatment of alpha-1 antitrypsin deficiency liver disease, achieved up to 92% knockdown in monkeys, thought to be near complete suppression of hepatic production of the alpha-1 antitrypsin protein. In non-GLP rat and monkey exploratory toxicology studies, no changes in clinical chemistries were observed and no histopathology suggestive of organ toxicity at doses up to 300 mg/kg (100x expected human dose). Arrowhead plans to file a CTA in Q1 2018 to initiate clinical studies, pending completion of GLP toxicology studies.
ARO-HBV, Arrowhead's third generation subcutaneously administered clinical candidate for the treatment of chronic hepatitis B virus infection, achieved up to 99.9% knockdown of hepatitis B surface antigen (HBsAg), e-antigen (HBeAg), and HBV DNA in rodent models. In a non-GLP rat exploratory toxicology study, no changes in clinical chemistries or histopathology changes suggestive of organ toxicity were observed at doses up to 300 mg/kg (75-100x expected human dose). Arrowhead plans to file a CTA in Q2 2018 to initiate clinical studies, pending completion of cross-reactivity and GLP toxicology studies.
ARO-APOC3 and ARO-ANG3
Arrowhead is expanding its cardiovascular disease portfolio utilizing the TRiM™ platform. Added to existing programs, ARO-LPA and ARO-AMG1, both partnered with Amgen; will be ARO-APOC3, targeting apolipoprotein C-III, and ARO-ANG3, targeting angiopoietin-like protein 3 (ANGPTL3). ARO-APOC3 and ARO-ANG3 will both be developed for the treatment of hypertriglyceridemia. CTA filings are planned for one or both candidates by the end of 2018.
For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Investors and Media:
News Provided by Acquire Media